CMS Revisits Part D "Protected Classes" Rule
This article was originally published in The Pink Sheet Daily
CMS drops proposal for a panel of outside experts, but still wants a "data-driven" process for selecting protected drug classes.
You may also be interested in...
Potential changes to current list of six protected classes will be reviewed by “expert panel” and subject to public rulemaking process.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.